https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/research-sheds-light-how-muscle-fibres-degenerate-duchenne-muscular-dystrophy/
Research sheds light on how muscle fibres degenerate in Duchenne Muscular Dystrophy
1 Oct 2018, 3:56 p.m.
A novel cell death process known as necroptosis is responsible for the degeneration of muscle cells over time in Duchenne muscular dystrophy (DMD), according to new research from the National Institute for Health Research (NIHR) Great Ormond Street Hospital (GOSH) Biomedical Research Centre. DMD, a serious neuromuscular condition that affects one in 5000 boys, is caused by errors in the dystrophin gene. This life-limiting condition causes muscle cells to be lost over time and scar tissue to build up making movement increasingly difficult.
In this study, researchers based at GOSH and the UCL Great Ormond Street Institute of Child Health (ICH) found that necroptosis, a newly-described mechanism of controlled cell death, plays a major role in the death of muscle fibres in dystrophin-deficient cells studied in the lab.
This research, led by Dr Maximilien Bencze, Research Associate at the Dubowitz Neuromuscular Centre at ICH, found that a protein called RIPK3 was involved in regulating death of muscle cells over time. They also found that less muscle cells die when RIPK3 was absent, pointing to a potential target for DMD therapies in the future. This cell death mechanism may also be involved in other neuromuscular disorders and this will be tested in future research.
The research was published in Nature Communications.
Work using human tissue samples was supported by NIHR via the GOSH BRC

New research analyses key immune cell
A new study led by researchers at University College London Great Ormond Street Institute of Child Health has found that women have a higher proportion of key immune cells between puberty and menopause.

First patient treated with groundbreaking gene therapy trial
A baby boy born with a rare condition has become the first in the world to be treated with a new, potentially lifechanging, investigational gene therapy on a clinical trial at Great Ormond Street Hospital (GOSH).

Reflecting on rare disease day 2025
Rare Disease Day is an international event which takes place annually on the last day of February. The date is chosen because in leap years it is February 29, the rarest date!

Genomics will revolutionise treatment for childhood rare diseases
A global study has proven the power of a simple genomics blood test to improve treatment and care for childhood epilepsy.